Frequently Asked Questions
The market is segmented based on , By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing), Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), Application (Screening, Companion Diagnostics, Others), End User (Hospitals, Clinics, Laboratories, Others) – Industry Trends and Forecast to 2029
.
The Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 592.56 USD Million in 2021.
The Global Clinical Oncology Next Generation Sequencing Market is projected to grow at a CAGR of 15.1% during the forecast period of 2022 to 2029.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
